Ibrutinib As Treatment for Chemoimmunotherapy-Resistant Patients with Follicular Lymphoma: First Results from the Open-Label, Multicenter, Phase 2 DAWN Study
Year: 2016
Type: article
Study design: Clinical Trial
Source: Blood
Authors: Ajay K. Gopal, Stephen J. Schuster, Nathan Fowler, Judith Trotman, Georg Hess, Jing-Zhou Hou, Abdulraheem Yacoub, Michael Lill, Peter Martin, Umberto Vitolo, Wojciech Jurczak, James Morton, Dzhelil Osmanov, Gary J. Gartenberg, Jessica Vermeulen, Sriram Balasubramanian, Shean-sheng Wang, Sanjay Deshpande, Gilles A. Salles
Institutions: Seattle Cancer Care Alliance, University of Washington, Fred Hutch Cancer Center, Abramson Cancer Center, University of Pennsylvania, The University of Texas MD Anderson Cancer Center, Concord Repatriation General Hospital, Johannes Gutenberg University Mainz, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, University of Kansas, The University of Kansas Health System, Cedars-Sinai Medical Center, Weill Cornell Medicine, Azienda Ospedaliera Citta' della Salute e della Scienza di Torino, Jagiellonian University, Icon (Australia), Russian Cancer Research Center NN Blokhin, Janssen Research & Development (United States), Janssen (Netherlands), Hôpital Lyon Sud
Language: English
Subfield: Genetics (clinical)
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2586466848